<?php
global $title;
$title = "Active Human IMPDH Type 2 Enzyme";

// META TAGS 
ob_start(); ?>
<title>Human IMPDH Type 2 (IMPDH2)</title>
<meta name="description" content="High-purity Human IMPDH Type 2 (IMPDH2) enzyme for research. Characterized for substrate affinity and inhibitor sensitivity. Ideal for drug discovery and cancer research.">
<meta name="keywords" content="Human IMPDH2, IMPDH Type 2, Inosine Monophosphate Dehydrogenase, IMPDH inhibitor screening, mycophenolic acid, ribavirin monophosphate, GTP biosynthesis, cancer research, immunosuppression, enzyme activity assay, E.C.1.1.1.205, drug discovery, NOVOCIB">

<!-- Open Graph / Facebook -->
<meta property="og:type" content="website">
<meta property="og:url" content="https://www.novocib.com/convenient-assay-kits/human-recombinant-impdh">
<meta property="og:title" content="Human IMPDH Type 2 (IMPDH2)">
<meta property="og:description" content="High-purity Human IMPDH Type 2 enzyme for research and drug discovery. Characterized for substrate affinity and inhibitor sensitivity.">
<meta property="og:image" content="https://www.novocib.com/app/img/IMPDH-reaction.png">

<!-- Twitter -->
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:title" content="Human IMPDH Type 2 (IMPDH2)">
<meta name="twitter:description" content="High-purity Human IMPDH Type 2 enzyme for research and drug discovery. Characterized for substrate affinity and inhibitor sensitivity.">
<meta name="twitter:image" content="https://www.novocib.com/app/img/IMPDH-reaction.png">

<!-- Canonical URL -->
<link rel="canonical" href="https://www.novocib.com/convenient-assay-kits/human-recombinant-impdh" />

<script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "Product",
        "name": "Human IMPDH Type 2 (IMPDH2) Enzyme",
        "description": "High-purity Human IMPDH Type 2 (IMPDH2) enzyme for research. Characterized for substrate affinity and inhibitor sensitivity. Ideal for drug discovery and cancer research.",
        "brand": {
            "@type": "Brand",
            "name": "NOVOCIB"
        },
        "url": "https://www.novocib.com/convenient-assay-kits/human-recombinant-impdh",
        "image": "https://www.novocib.com/app/img/IMPDH-reaction.png",
        "category": "Research Enzymes",
        "sku": "IMPDH2-50U",
        "offers": {
            "@type": "Offer",
            "url": "https://www.novocib.com/convenient-assay-kits/human-recombinant-impdh",
            "priceCurrency": "USD",
            "availability": "https://schema.org/InStock"
        },
        "mainEntity": [{
            "@type": "FAQPage",
            "mainEntity": [{
                "@type": "Question",
                "name": "What is IMPDH Type 2 and what is its biological significance?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "IMPDH Type 2 (IMPDH2) is a key enzyme in the de novo biosynthesis of guanine nucleotides. It converts inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP), which is a crucial step in the production of GTP and dGTP. This enzyme is particularly important in rapidly dividing cells and is a validated target for immunosuppressive, antiviral, and anticancer therapies."
                }
            }, {
                "@type": "Question",
                "name": "What are the main applications of Human IMPDH2?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "Human IMPDH2 is widely used in drug discovery for cancer and autoimmune diseases, antiviral research, nucleotide metabolism studies, and high-throughput screening of potential enzyme inhibitors. It's particularly valuable for studying the mechanism of action of immunosuppressants like mycophenolic acid and ribavirin."
                }
            }, {
                "@type": "Question",
                "name": "What quality controls are performed on the IMPDH2 enzyme?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "Each batch of Human IMPDH2 undergoes rigorous quality control including: activity assays to ensure specific activity, SDS-PAGE analysis for purity assessment, endotoxin testing, and functional validation in inhibitor screening assays. The enzyme is provided with a detailed Certificate of Analysis."
                }
            }, {
                "@type": "Question",
                "name": "What is the recommended storage and handling for IMPDH2?",
                "acceptedAnswer": {
                    "@type": "Answer",
                    "text": "The lyophilized enzyme should be stored at -20°C. Upon reconstitution, the enzyme should be aliquoted and stored at -80°C. Avoid repeated freeze-thaw cycles. The enzyme remains stable for at least 6 months when stored properly. Always keep the enzyme on ice when in use."
                }
            }]
        }]
    }
</script>
<?php $metas = ob_get_clean();


require_once $_SERVER['DOCUMENT_ROOT'] . "/app/templates/new_base.php";
echo Banner::gen();
?>

<section class="container mt-5">
    <h1 class="underlinedTitle right"><span class="underlined novoblue right">Human IMPDH, Type II (IMPDH2)</span></h1>
    <div class="row">
        <div class="col-lg-6">
            <p>
                <b>Synonyms:</b>
                inosine 5'-monophosphate dehydrogenase, type 2, IMP dehydrogenase, type II, IMPDH2.
            </p>
            <p>
                Inosine 5'-monophosphate dehydrogenase type 2 (IMPDH 2, E.C.1.1.1.205) is the predominant
                isoform of IMPDH and a validated target to treat a wide range of cancers and infectious
                diseases and to prevent lymphocytes proliferation.
            </p>
            <p>
                <b>Catalytic activity</b>
                <br />
                Inosine Monophosphate Dehydrogenase (IMPDH) converts inosine 5µ-monophosphate (IMP) to
                xanthosine 5µ-monophosphate (XMP) using NAD+ as a cofactor.
            </p>
            <p>
                The oxidation of IMP to XMP is considered as the pivotal step in the biosynthesis of guanine
                nucleotide, whose pool controls cell proliferation and many other major cellular processes(1).
                The decrease in guanine nucleotide resulting from IMPDH inhibition interrupts the nucleic acid
                synthesis in proliferating cells. The involvement of IMPDH in de novo guanine nucleotide
                biosynthesis makes IMPDH a crucial enzyme in cell proliferation and differentiation(2). IMPDH
                is recognized as a validated target for several major therapeutic areas. IMPDH inhibitors are
                exploited as antiviral (e.g. ribavirine), antiparasitic, antimicrobial, antileukemic, and
                immunosuppressive agents(2). IMPDH Type II is the predominant isoform of the enzyme and is
                selectively expressed in proliferating cells, including lymphocytes and tumor cells(2).
            </p>
            <p>
                <strong class="novo-blue">NOVOCIB's</strong>
                IMPDH 2 has been cloned by RT-PCR amplification of mRNA extracted from human hepatoma cells
                (NP_000875.2, 100% identity) and expressed in E.coli.
            </p>
            <p>
                <strong class="novo-blue">NOVOCIB's</strong>
                purified IMPDH 2 is an active enzyme characterized for its affinity for inosine
                5'-monophosphate and NAD substrates, and its sensitivity to enzyme inhibitors such as
                mycophenolic acid and ribavirine-monophosphate.
            </p>
            <p>
                <strong>Unit Definition:</strong>
                One unit of IMPDH Type II catalyzes the oxydation of 1 µmole of IMP to XMP per minute at pH
                8.8 at 37 µC.
            </p>
            <p>
                <b>High Specific Activity:</b>
                > 200 mU/mg protein.
            </p>
        </div>
        <div class="col-lg-6 text-center d-flex align-items-center">
            <div>
                <img
                class="img-fluid mb-3"
                src="/app/img/IMPDH-reaction.png"
                alt="Human IMPDH Type 2 enzymatic reaction: IMP + NAD+ → XMP + NADH + H+"
                title="IMPDH Type 2 Catalytic Reaction"
                loading="lazy" />
            <h4 class="novo-blue">Human IMPDH Type 2</h4>
            <h5>Ref. #E-Nov1</h5>
            </div>
        </div>
        <div class="d-flex justify-content-center mt-4" itemscope itemtype="https://schema.org/Product">
            <meta itemprop="name" content="Human IMPDH Type 2">
            <meta itemprop="description" content="High-purity Human IMPDH Type 2 enzyme for research and drug discovery applications.">
            <div itemprop="brand" itemtype="https://schema.org/Brand" itemscope>
                <meta itemprop="name" content="NOVOCIB">
            </div>
            <div class="col-lg-10 col-12">
                <?= Products::gen("Human IMPDH Type 2") ?>
                <div class="text-center" itemprop="offers" itemscope itemtype="https://schema.org/Offer">
                    <p class="mb-2">
                        <strong>Product Code: </strong><span itemprop="sku">E-Nov1</span>
                    </p>
                    <p class="mb-2">
                        <b>Kit is provided in stable lyophilized form and
                            <span class="text-danger">shipped without dry ice</span></b>
                    </p>
                    <meta itemprop="priceCurrency" content="USD">
                    <link itemprop="availability" href="https://schema.org/InStock">
                </div>
                <p class="my-4 text-center">
                    <strong>
                        You can ask us for a quotation
                        <a href="mailto:contact@novocib.com">here</a>
                        or write at
                        <a href="mailto:contact@novocib.com">contact@novocib.com</a>
                    </strong>
                </p>
            </div>
        </div>
    </div>
    <p class="text-center text-lg-end"><i class="fa-solid fa-download"></i> Download our brochure <a target="_blank" href="/app/documents/NovoCIB IMPDH Services.pdf">"NovoCIB's IMPDH Products & Services" <i class="fa-regular fa-file-pdf"></i></a></p>
</section>

<section class="bg-light py-3 mt-3">
    <div class="container">
        <p>
            <strong>Assay condition:</strong>
            KH2PO4 0.1M, pH8.8, NAD 250µM, DTT 2.5mM, 2.5mU/ml of human recombinant IMPDH II, Incubation
            at 37µC. Reaction started by adding IMP at 250µM final concentration. NADH formation was
            followed in an iEMS Reader MF (Labsystems) plate reader at 340nm.
        </p>
        <div class="row justify-content-center">
            <div class="col-lg-2 col-4 my-4">
                <img height="400" class="img-fluid" src="/app/img/IMPDH-Gel.png" alt="SDS-PAGE analysis of purified Human IMPDH Type 2 showing high purity" loading="lazy" />
            </div>
            <div class="col-lg-8 my-4">
                <img height="400" class="img-fluid" src="/app/img/IMPDH-IC50.png" alt="Dose-response curve showing IMPDH Type 2 inhibition by mycophenolic acid" loading="lazy" />
            </div>
        </div>
        <p class="text-end mt-4">
            <strong>
                Download this Document:
                <a target="_blank" href="/app/documents/NovoCIB E-Nov1.pdf">
                    "NOVOCIB's Human Recombinant IMPDH"
                    <i class="fa-regular fa-file-pdf"></i>
                </a>
            </strong>
        </p>
        <p class="text-end">
            <strong>
                Download this Document:
                <a target="_blank" href="/app/documents/NovoCIB IMPDH Services.pdf">
                    "NOVOCIB - IMPDH Products & Services"
                    <i class="fa-regular fa-file-pdf"></i>
                </a>
            </strong>
        </p>
    </div>
</section>
<section class="container my-5">
    <h3 class="text-center text-primary mb-4">How to measure the activity of IMPDH 2</h3>
    <ol class="list-group list-group-numbered mb-4">
        <li class="list-group-item">Resuspend the content of the tube with lyophilized IMPDH type 2 (50–100 mU) in 200 µL of deionized water.</li>
        <li class="list-group-item">Prepare fresh reaction buffer: 1 mL of 50 mM KH₂PO₄ pH 8.5, 5 mM DTT*, 1 mM IMP*, 36°C.</li>
        <li class="list-group-item">Add 20 µL of IMPDH (or 10 µL for 100 µL) per 1 mL of buffer without NAD*.</li>
        <li class="list-group-item">Add 200 µL of this mixture to 4 wells and preincubate at 36°C for 10 min.</li>
        <li class="list-group-item">To start the reaction, add 5 µL of 40 mM NAD (1 mM final concentration) to 2 wells, leaving 2 others as a blank.</li>
        <li class="list-group-item">Follow the reaction at 340 nm and 25–36°C.</li>
    </ol>
    <p class="text-muted"><em>*For best results, always use freshly prepared solutions of DTT, IMP, and NAD.</em></p>

    <h5 class="mt-5 mb-3 text-center text-secondary">Absorbance at 340 nm (200 µL per well, Corning® 3797 microplate)</h5>
    <div class="table-responsive">
        <table class="table table-bordered table-striped text-center">
            <thead class="table-light">
                <tr>
                    <th>Time (min)</th>
                    <th>IMP 1 mM, no NAD</th>
                    <th>IMP 1 mM, no NAD (duplicate)</th>
                    <th>IMP 1 mM + 1 mM NAD</th>
                    <th>IMP 1 mM + 1 mM NAD (duplicate)</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>0</td>
                    <td>0.118</td>
                    <td>0.116</td>
                    <td>0.167</td>
                    <td>0.165</td>
                </tr>
                <tr>
                    <td>1</td>
                    <td>0.118</td>
                    <td>0.116</td>
                    <td>0.205</td>
                    <td>0.203</td>
                </tr>
                <tr>
                    <td>2</td>
                    <td>0.119</td>
                    <td>0.117</td>
                    <td>0.244</td>
                    <td>0.240</td>
                </tr>
                <tr>
                    <td>3</td>
                    <td>0.120</td>
                    <td>0.116</td>
                    <td>0.283</td>
                    <td>0.278</td>
                </tr>
                <tr>
                    <td>4</td>
                    <td>0.121</td>
                    <td>0.116</td>
                    <td>0.322</td>
                    <td>0.316</td>
                </tr>
                <tr>
                    <td>5</td>
                    <td>0.121</td>
                    <td>0.116</td>
                    <td>0.362</td>
                    <td>0.354</td>
                </tr>
                <tr>
                    <td>6</td>
                    <td>0.121</td>
                    <td>0.116</td>
                    <td>0.401</td>
                    <td>0.392</td>
                </tr>
                <tr>
                    <td>7</td>
                    <td>0.122</td>
                    <td>0.116</td>
                    <td>0.440</td>
                    <td>0.430</td>
                </tr>
            </tbody>
        </table>
    </div>

    <h5 class="mt-4">Calculated Slopes (AU/min)</h5>
    <ul class="list-group mb-3">
        <li class="list-group-item">IMP 1 mM, no NAD: 0.0006</li>
        <li class="list-group-item">IMP 1 mM, no NAD (duplicate): 0</li>
        <li class="list-group-item">IMP 1 mM + 1 mM NAD: 0.0391</li>
        <li class="list-group-item">IMP 1 mM + 1 mM NAD (duplicate): 0.0378</li>
    </ul>

    <h5>Slope Mean (AU/min)</h5>
    <ul class="list-group mb-3">
        <li class="list-group-item">IMP 1 mM, no NAD: 0.0003</li>
        <li class="list-group-item">IMP 1 mM + 1 mM NAD: 0.0385</li>
    </ul>

    <h5>Slope After Blank Subtraction</h5>
    <p class="mb-3">AU/min: <strong>0.0382</strong></p>

    <h5>Enzyme Activity Calculations</h5>
    <ul class="list-group">
        <li class="list-group-item">Activity in well (U/mL): 0.00796</li>
        <li class="list-group-item">Dilution factor (20 µL per 1 mL): ×50</li>
        <li class="list-group-item">Activity of enzyme solution (U/mL): <strong>0.398</strong></li>
        <li class="list-group-item">Amount of enzyme per tube (Units): <strong>0.080</strong></li>
    </ul>

    <!-- Include Chart.js -->
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>

    <div class="container my-5">
        <h5 class="text-center text-secondary mb-4">Kinetics of NADH Formation</h5>
        <canvas id="nadGraph" width="600" height="400"></canvas>
    </div>

    <script>
        const ctx = document.getElementById('nadGraph').getContext('2d');
        const nadGraph = new Chart(ctx, {
            type: 'line',
            data: {
                labels: [0, 1, 2, 3, 4, 5, 6, 7],
                datasets: [{
                        label: 'IMP 1mM, no NAD',
                        data: [0.118, 0.118, 0.119, 0.120, 0.121, 0.121, 0.121, 0.122],
                        borderColor: 'blue',
                        fill: false
                    },
                    {
                        label: 'IMP 1mM, no NAD (duplicate)',
                        data: [0.116, 0.116, 0.117, 0.116, 0.116, 0.116, 0.116, 0.116],
                        borderColor: 'orange',
                        fill: false
                    },
                    {
                        label: 'IMP 1mM + 1mM NAD',
                        data: [0.167, 0.205, 0.244, 0.280, 0.322, 0.362, 0.401, 0.440],
                        borderColor: 'gray',
                        fill: false
                    },
                    {
                        label: 'IMP 1mM + 1mM NAD (duplicate)',
                        data: [0.165, 0.203, 0.241, 0.276, 0.316, 0.354, 0.392, 0.430],
                        borderColor: 'gold',
                        fill: false
                    }
                ]
            },
            options: {
                scales: {
                    x: {
                        title: {
                            display: true,
                            text: 'Time (min)'
                        }
                    },
                    y: {
                        title: {
                            display: true,
                            text: 'Absorbance at 340 nm'
                        }
                    }
                }
            }
        });
    </script>

</section>

<section class="bg-white py-4">
    <div class="container">
        <h2 class="novo-blue mb-4 text-center">IMPDH - A Key Target for Therapeutic Applications</h2>
        <div class="row">
            <div class="col-lg-8 mx-auto">
                <div class="card shadow-sm mb-4">
                    <div class="card-body">
                        <h3 class="h5 card-title">Key Features:</h3>
                        <ul class="list-unstyled">
                            <li class="mb-2"><i class="fas fa-check-circle text-success me-2"></i> High-purity human recombinant IMPDH Type 2</li>
                            <li class="mb-2"><i class="fas fa-check-circle text-success me-2"></i> Fully characterized enzyme activity</li>
                            <li class="mb-2"><i class="fas fa-check-circle text-success me-2"></i> Validated for inhibitor screening</li>
                            <li class="mb-2"><i class="fas fa-check-circle text-success me-2"></i> Suitable for cancer and immunology research</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>
        <div class="container py-4">
            <ol>
                <li class="my-3"><b>Identify</b> IMPDH2 inhibitors using NOVOCIB’s IMPDH type 2 or PRECISE IMPDH2 assay kit.</li>
                <li class="my-3"><b>Compare</b> against known inhibitors like MPA or ribavirin.</li>
                <li class="mt-3"><b>Confirm</b> GTP depletion in inhibitor-treated cells using NOVOCIB’s <b>Cellular Nucleotide Profiling (HPLC-UV)</b>.</li>
            </ol>
            <div class="mt-3 mb-4 text-center">
                <a target="_blank" href="/analytical-services/cellular-nucleotides-analysis" class="btn btn-primary">
                    <img src="/app/img/icons/custom_cell.svg" class="icon" alt="Cell icon">
                    Cellular Nucleotides Analysis
                    <i class="fa-solid fa-arrow-up-right-from-square"></i>
                </a>
            </div>

            <p>To validate IMPDH2 inhibitors identified in vitro, try our analytical service that measures guanine nucleotide depletion and related metabolic changes. These assays confirm whether compounds active in biochemical screens also suppress nucleotide synthesis in living cells.</p>

            <ul>
                <li class="my-3">Quantifies &gt;30 ribo- and deoxyribonucleotides (mono-, di-, triphosphates) in a single run.</li>
                <li class="my-3">Used to measure depletion of GTP pools in cells treated with IMPDH inhibitors.</li>
                <li class="my-3">Validated reference inhibitors <b>include mycophenolic acid (MPA), hydroxyurea (HU), methotrexate (MTX)</b>, and <b>ribavirin</b>.</li>
            </ul>

        </div>

        <h2 class="h4 text-primary mt-4">Therapeutic Applications of IMPDH2</h2>
        
        <div class="card mb-4 border-0 shadow-sm">
            <div class="card-header bg-light">
                <h3 class="h5 mb-0">IMPDH in Immunology and Autoimmune Diseases</h3>
            </div>
            <div class="card-body">
                <p>IMPDH plays a critical role in lymphocyte proliferation and immune response modulation, making it a prime target for:</p>
                <ul class="list-unstyled">
                    <li><i class="fas fa-check-circle text-success me-2"></i> <strong>Immunosuppressive Therapies:</strong> CellCept® (mycophenolate mofetil), a prodrug of mycophenolic acid, is a well-established IMPDH inhibitor used in organ transplantation and autoimmune conditions.</li>
                    <li class="mt-2"><i class="fas fa-check-circle text-success me-2"></i> <strong>Autoimmune Disease Management:</strong> IMPDH inhibitors show significant promise in treating various autoimmune disorders including:</li>
                    <ul class="list-unstyled ms-4 mt-2">
                        <li>• Systemic Lupus Erythematosus (SLE)</li>
                        <li>• Rheumatoid Arthritis (RA)</li>
                        <li>• Psoriasis</li>
                        <li>• Myasthenia Gravis</li>
                        <li>• Lupus Nephritis</li>
                    </ul>
                </ul>
            </div>
        </div>

        <div class="card mb-4 border-0 shadow-sm">
            <div class="card-header bg-light">
                <h3 class="h5 mb-0">IMPDH in Oncology and Cancer Research</h3>
            </div>
            <div class="card-body">
                <p>IMPDH Type 2 is overexpressed in many cancer cells, making it an attractive target for anticancer therapies:</p>
                <div class="row">
                    <div class="col-md-6">
                        <h4 class="h6">Key Cancer Targets</h4>
                        <ul>
                            <li>Acute Myelogenous Leukemia (AML)</li>
                            <li>Chronic Myelogenous Leukemia (CML)</li>
                            <li>Pancreatic cancer</li>
                            <li>Colorectal cancer</li>
                            <li>Bladder cancer</li>
                        </ul>
                    </div>
                    <div class="col-md-6">
                        <h4 class="h6">Therapeutic Advantages</h4>
                        <ul>
                            <li>Overcomes drug resistance in cancer cells</li>
                            <li>Enhances efficacy of other anticancer drugs</li>
                            <li>Targets rapidly dividing cancer cells</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>

        <div class="card border-0 shadow-sm">
            <div class="card-header bg-light">
                <h3 class="h5 mb-0">Current IMPDH Inhibitors in Development</h3>
            </div>
            <div class="card-body">
                <div class="row">
                    <div class="col-md-6">
                        <h4 class="h6">Approved Drugs</h4>
                        <ul class="list-unstyled">
                            <li><i class="fas fa-pills text-primary me-2"></i> <strong>CellCept®</strong> (mycophenolate mofetil)</li>
                            <li><i class="fas fa-pills text-primary me-2"></i> <strong>Ribavirin</strong> (antiviral)</li>
                            <li><i class="fas fa-pills text-primary me-2"></i> <strong>Mizoribine</strong> (immunosuppressant)</li>
                            <li><i class="fas fa-pills text-primary me-2"></i> <strong>Tiazofurine</strong> (antineoplastic)</li>
                        </ul>
                    </div>
                    <div class="col-md-6">
                        <h4 class="h6">Promising Candidates</h4>
                        <ul class="list-unstyled">
                            <li><i class="fas fa-flask text-success me-2"></i> <strong>AVN-944</strong> - In trials for hematologic malignancies and solid tumors</li>
                            <li><i class="fas fa-flask text-success me-2"></i> <strong>Benzamide riboside</strong> - Phase II/III for leukemia</li>
                            <li><i class="fas fa-flask text-success me-2"></i> <strong>Novel small molecules</strong> - Multiple candidates in preclinical development</li>
                        </ul>
                    </div>
                </div>
                <p class="mt-3 mb-0">The continued elucidation of IMPDH's atomic structure and mechanism of action continues to drive the development of more potent and selective inhibitors, opening new possibilities for targeted therapies across multiple disease areas.</p>
            </div>
        </div>
    </div>
    <div class="container">
        <div class="row justify-content-evenly">
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">AVN-944</figcaption>
                <img class="w-100" src="/app/img/AVN-944.png" alt="AVN-944 Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">VX-148</figcaption>
                <img class="w-100" src="/app/img/VX-148.png" alt="VX-148 Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">VX-497</figcaption>
                <img class="w-100" src="/app/img/VX-497.png" alt="VX-497 Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">MPA (mycophenolic acid)</figcaption>
                <img class="w-100" src="/app/img/MPA.png" alt="MPA Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">CellCept®</figcaption>
                <img class="w-100" src="/app/img/MMF.png" alt="MMF Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">BMS-337197</figcaption>
                <img class="w-100" src="/app/img/BMS-337197.png" alt="BMS-337197 Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">Tiazofurin</figcaption>
                <img class="w-100" src="/app/img/tiazofurin.png" alt="Tiazofurin Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">CellCept®</figcaption>
                <img class="w-100" src="/app/img/ribavirine.png" alt="Ribavirine Structure" />
            </figure>
            <figure class="col-lg-3 col-6 border">
                <figcaption class="text-center">Mizoribine</figcaption>
                <img class="w-100" src="/app/img/mizoribine.png" alt="Mizoribine Structure" />
            </figure>
        </div>
    </div>
</section>

<section class="bg-light">
    <div class="referances row justify-content-center">
        <h5 class="text-center py-3 w-100">
            Scentific References siting Novocib's IMPDH2 inhibitors
            <i class="novo-blue fa-solid fa-arrow-up-right-from-square ms-2"></i>
        </h5>
        <div class="col-2 d-none d-md-block">
            <img src="/app/img/icons/book.svg" class="w-100" alt="book logo">
        </div>

        <div class="col-8">
            <ol>
                <li>
                    <a target="_blank" rel="noopener" href="https://aces.onlinelibrary.wiley.com/doi/10.1002/ajoc.202500584" title="Go to article on Wiley Online Library">
                        <em>S. Puri, Shalini, K. Juvale, S. Kirubakaran</em><br>
                        Design and Development of New Benzopyrazole Derivatives as Selective Inhibitors of Helicobacter pylori IMPDH Asian Journal of Organic Chemistry. 2025, e00584.
                    </a>
                </li>
                <li>
                    <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/39369481/" title="Go to PubMed">
                        <em>Ayoub N, Upadhyay A, Tête A, Pietrancosta N, Munier-Lehmann H, O'Sullivan TP.</em><br>
                        Synthesis, evaluation and mechanistic insights of novel IMPDH inhibitors targeting ESKAPEE bacteria. Eur J Med Chem. 2024 Dec 15;280:116920. doi: 10.1016/j.ejmech.2024.116920. Epub 2024 Sep 27. PMID: 39369481.
                    </a>
                </li>
                <li>
                    <a target="_blank" rel="noopener" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6009919/" title="Go to NIH">
                       <em>Shah CP, Kharkar PS.</em><br>Newer human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents. J Enzyme Inhib Med Chem. 2018 Dec;33(1):972-977. doi: 10.1080/14756366.2018.1474211. PMID: 29792360; PMCID: PMC6009919.
                    </a>
                </li>
                <li>
                    <a target="_blank" rel="noopener" href="https://www.sciencedirect.com/science/article/abs/pii/S0223523418307888" title="Go to ScienceDirect">
                       <em>Chetan P. Shah, Prashant S. Kharkar</em><br>Discovery of novel human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2) inhibitors as potential anticancer agents,
                       European Journal of Medicinal Chemistry, Volume 158, 2018, Pages 286-301
                    </a>
                </li>
                <li>
                    <a target="_blank" rel="noopener" href="https://pubmed.ncbi.nlm.nih.gov/23346382/" title="Go to PubMed">
                        <em>Matyugina ES, Andreevskaya SN, Smirnova TG, Khandazhinskaya AL.</em><br>Carbocyclic analogues of inosine-5'-monophosphate: synthesis and biological activity. Acta Naturae. 2012 Oct;4(4):73-7. PMID: 23346382; PMCID: PMC3549521.
                    </a>
                </li>
                <li>
                    <a target="_blank" rel="noopener" href="https://ashpublications.org/blood/article/144/Supplement%201/1602/532191/Inosine-Monophosphate-Dehydrogenase-2-IMPDH2-As" title="Go to Blood journal">
                       <em>Johnvesly Basappa, Shengchun Wang, Cosimo Lobello, David Rushmore, Olga Melnikov, Neil Sen, Vinay Mallikarjuna, Priyanka Jain, Pin Lu, Y. Lynn Wang, Kathy Cai, Reza Nejati, Aaron Goldman, Mariusz Wasik</em><br>
                        Inosine Monophosphate Dehydrogenase-2 (IMPDH2) As the Potential Novel Therapeutic Target in Mantle Cell Lymphoma (MCL): The Underlying Tyrosine Phosphorylation-Based Activation Mechanism and Translational Implications. Blood 2024; 144 (Supplement 1): 1602
                </li>
            </ol>
        </div>
    </div>
</section>